Dr. Jerald Radich highlights meaningful posters in chronic myeloid leukemia
“AI is everywhere. Is it useful in CML? This study tests three different AI engines in their ability to answer 25 clinically meaningful
Acute Myeloid Leukemia
SOHO 2026
Trending now
Meetings / Conferences
SOHO 2026
News
Advancing care means protecting the environment that makes discovery possible
These past two years have been plagued with instability, whether perceived or real, as well as a lack of transparency. The current environment
Lymphoma News
SOHO 2026
News
SOHO 2026: Pharma trials in lymphoma with Drs. Nastoupil, Shah
At 8 am on Wednesday, September 9 during the SOHO 2026 Annual Meeting, Nirav Shah, MD, will lead a Meet-the-Professor session on pharma
MDS News
SOHO 2026
Meetings / Conferences
Video Interviews
What can research funding entities do to help progress in MDS with Timothy Graubert, MD
The conversation covers how funding organizations support the international MDS research community by deploying flexible financial resources, offering faculty transition awards to build
Acute Lymphoblastic Leukemia News
Leukemia News
SOHO 2026
Cellular Therapy
Leukemia
Acute Lymphoblastic Leukemia
News
Video Interviews
Dr. DiPersio previews the SOHO 2026 ALL session to be held on Wednesday, September 9
The discussion focuses on whether patients in complete molecular remission still need an allogeneic stem cell transplant, alongside methods to prevent T-cell fratricide
Myeloproliferative Neoplasms
Polycythemia Vera
News
FDA approves first-in-class therapy for polycythemia vera
The approval was supported by results from the global randomized phase 3 VERIFY trial involving 293 patients, which showed that patients receiving rusfertide
SOHO 2026
News
Society Updates
What is the SOHO Ambassador program?
In this SOHO Insider video interview, Elias Jabbour, MD, professor of medicine in the department of leukemia at The University of Texas MD
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
Where do CELMoDs, including mezigdomide and iberdomide, fit in the myeloma treatment landscape?
Clinical investigators are actively evaluating these novel agents across several strategic combinations and settings, Prof. Weisel explained. "We have very interesting maintenance trials,"
Trending now
Leukemia
Myelodysplastic Syndromes
News
FDA approves first targeted therapy for warm autoimmune hemolytic anemia
The approval is based on the Phase 2/3 ENERGY study, the full results of which were presented at the European Hematology Association 2026
Multiple Myeloma
News
NMPA grants approval to felzartamab in multiple myeloma
The China National Medical Products Administration (NMPA) has approved felzartamab (Jingfei), a human monoclonal antibody targeting CD38, in combination with lenalidomide and dexamethasone